Background
Methods
Study design and population
Data collection
Best-case definition
Variables and statistical analyses
Sample size
Results
Variables | 15 AA-related BC cases | 184 other BC cases | |||
---|---|---|---|---|---|
Mean (SD) | Number (%) | Mean (SD) | Number (%) | ||
DNA adducts×108 nucleotides (ln) | 1.40 (1.5) | 0.76 (1.2) | |||
≥1 | 11 (73.3) | 69 (37.5) | |||
Age (years) | 60.0 (10.4) | 63.4 (11.2) | |||
≤ 56.9 years | 7 (46.7) | 43 (23.4) | |||
57–65.9 years | 3 (20.0) | 50 (27.2) | |||
66–70.9 years | 3 (20.0) | 44 (23.9) | |||
≥ 71 years | 2 (13.3) | 47 (25.5) | |||
Smoking (categories) | |||||
Non Smokers & Ex Smokers quitting >20 years | 2 (13.3) | 35 (19.0) | |||
Ex Smokers quitting <20 years | 1 (6.7) | 60 (32.6) | |||
Current smokers | 12 (75.0) | 87 (47.3) | |||
Pack years (cigarettes smoked lifetime) | 31.5 (12.3) | 35.6 (26.2) | |||
≤ 18.9 | 1 (6.7) | 46 (25.1) | |||
19–32.9 | 8 (53.3) | 45 (24.6) | |||
33–46.9 | 4 (26.7) | 46 (24.6) | |||
≥ 47 | 2 (13.3) | 47 (25.7) | |||
Coffee consumption (weighted mean) | 2.1 (1.7) | 2.4 (2.4) | |||
≤ 1 cup/day | 6 (40.0) | 71 (38.8) | |||
2 cups/day | 4 (26.7) | 36 (19.7) | |||
3 caps/day | 3 (20.0) | 32 (17.5) | |||
≥ 4 cups/day | 2 (13.3) | 44 (24.0) | |||
Genotypes (legend below) |
GSTM1
| 12 (80.0) | 117 (63.9) | ||
GSTT1
| 3 (20.0) | 38 (20.8) | |||
GSTP
| 5 (33.3) | 92 (50.3) | |||
NAT1
| 4 (26.7) | 60 (32.8) | |||
NAT2
| 10 (66.7) | 111 (60.7) | |||
MPO
| 1 (6.7) | 6 (3.3) | |||
COMT
| 7 (46.7) | 132 (72.1) | |||
MnSOD
| 4 (26.7) | 63 (34.4) | |||
CYP1B1
| 12 (80.0) | 156 (82.3) | |||
XRCC1
| 7 (46.7) | 98 (53.4) | |||
XRCC3
| 6 (40.0) | 103 (56.3) | |||
XPD
| 7 (46.7) | 113 (61.8) |
Variables | Classes | Full model | Short model | ||||
---|---|---|---|---|---|---|---|
OR | 95% CI |
p-value | OR | 95% CI |
p-value | ||
Age (years)a
| 57–65.9 | 0.12 | 0.01–0.98 | 0.048 | |||
66–70.9 | 0.29 | 0.04–2.25 | 0.239 | ||||
≥ 71 | 0.10 | 0.01–1.07 | 0.056 | ||||
Smokingb
| Ex-smokers | 0.05 | 0.00–1.47 | 0.083 | 0.11 | 0.01–1.49 | 0.096 |
Smokers | 1.16 | 0.16–8.60 | 0.887 | 1.56 | 0.31–7.94 | 0.589 | |
Coffee consumptionc
| 2 | 0.63 | 0.09–4.64 | 0.654 | |||
3 | 1.96 | 0.27–14.24 | 0.505 | ||||
≥4 | 0.05 | 0.00–0.86 | 0.039 | ||||
DNA adductsd
| ≥1 | 19.20 | 2.52–146. | 0.004 | 6.02 | 1.66–21.8 | 0.006 |
Genotypese
|
GSTM1
| 3.01 | 0.51–17.7 | 0.223 | |||
GSTT1
| 0.29 | 0.04–1.92 | 0.198 | ||||
GSTP1
| 0.19 | 0.03–1.08 | 0.061 | 0.41 | 0.12–1.38 | 0.150 | |
NAT1
| 0.27 | 0.05–1.52 | 0.139 | ||||
NAT2
| 2.55 | 0.52–12.6 | 0.25 | ||||
MPO
| 1.38 | 0.03–65.1 | 0.871 | ||||
COMT
| 0.05 | 0.01–0.39 | 0.005 | 0.21 | 0.06–0.72 | 0.014 | |
MnSOD
| 0.30 | 0.06–1.49 | 0.142 | ||||
CYP1B1
| 0.27 | 0.03–2.42 | 0.24 | ||||
XRCC1
| 0.97 | 0.22–4.22 | 0.966 | ||||
XRCC3
| 0.38 | 0.09–1.68 | 0.203 | 0.40 | 0.12–1.34 | 0.139 | |
XPD
| 0.31 | 0.05–1.81 | 0.195 | ||||
Constant term | 5.95 | 0.06–545. | 0.439 | 0.18 | 0.03–1.30 | 0.09 | |
Reference groups: apatients with ≤56.9 years; bnon smokers and ex-smokers from >20 years; cpatients with consumption of ≤1 cup/day; dpatients with <1 (logarithm values) of DNA adducts×108 nucleotides; epatients with genotype values set at 0 (see text for definition). | |||||||
Measures of fit for logistic regression | Full model | Short model | |||||
R-square | 0.389 | 0.228 | |||||
Area under the ROC curve | 0.931 | 0.856 | |||||
Pearson chi-square test: |
p-value | 0.087 | 0.826 | ||||
no. covariates | 197 | 44 | |||||
Hosmer-Lemeshow test: |
p-value | 0.130 | 0.942 | ||||
no. groups | 10 | 10 |
Classified | True | Total | Classified | True | Total | ||
---|---|---|---|---|---|---|---|
D | –D | D | –D | ||||
Positive | 13 | 15 | 28 | Positive | 13 | 47 | 60 |
Negative | 2 | 169 | 171 | Negative | 2 | 137 | 139 |
Total | 15 | 184 | 199 | Total | 15 | 184 | 199 |
Sensitivity | 86.7% | Sensitivity | 86.7% | ||||
Specificity | 91.9% | Specificity | 74.5% | ||||
Positive predictive value | 46.4% | Positive predictive value | 21.7% | ||||
Negative predictive value | 98.8% | Negative predictive value | 98.6% | ||||
Correctly classified | 91.5% | Correctly classified | 75.4% | ||||
Net Benefit per 100 patients | +4.9 | Net Benefit per 100 patients | + 4.1 |
Classified | True | Total | Classified | True | Total | ||
---|---|---|---|---|---|---|---|
D | –D | D | –D | ||||
Positive | 14 | 34 | 48 | Positive | 14 | 73 | 87 |
Negative | 1 | 150 | 151 | Negative | 1 | 111 | 112 |
Total | 15 | 184 | 199 | Total | 15 | 184 | 199 |
Sensitivity | 93.3% | Sensitivity | 93.3% | ||||
Specificity | 81.5% | Specificity | 60.3% | ||||
Positive predictive value | 29.2% | Positive predictive value | 16.1% | ||||
Negative predictive value | 99.3% | Negative predictive value | 99.1% | ||||
Correctly classified | 82.4% | Correctly classified | 62.8% | ||||
Net Benefit per 100 patients | + 5.3 | Net Benefit per 100 patients | + 5.1 |